 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Adamas Pharmaceuticals, Inc. (ADMS) discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders.
The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
The company's products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy.
Shares have formed a bullish "flag" after the Food and Drug Administration approved its Parkinson’s drug, Gocovri. The drug has been approved to treat involuntary movements, called dyskinesia. This disorder is common with Parkinson’s patients when they’re on levodopa-based therapy, which is the standard treatment. Gocovri is the first of its kind to be approved by the FDA.
With no drug approved for treating dyskinesia, the approval of Gocovri is good news for Adamas. The company expects to make the drug available in the fourth quarter of 2017 and a formal launch is planned in January 2018. Higher share prices are expected for this stock.
52-Weeks Trading Range: $12.10 to $22.58
Entry Point: $21.50
Stop Loss: $20.00
Target Price: $23.40
ADMS closed at $23.50
